Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
NeuroSense Therapeutics Ltd. (NRSN) had Weighted-Average Shares Outstanding (Diluted) of 18.60M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-10.21M |
|
-- |
|
-- |
|
$9.90M |
|
$-9.90M |
|
$-0.31M |
|
$-10.21M |
|
$-10.21M |
|
$-10.21M |
|
$-10.21M |
|
$-10.21M |
|
$-10.21M |
|
$-9.90M |
|
$-9.88M |
|
18.60M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
18.60M |
$-0.54 |
|
$-0.54 |
|
| Balance Sheet Financials | |
$4.40M |
|
$0.07M |
|
$0.17M |
|
$4.58M |
|
$1.99M |
|
-- |
|
-- |
|
$1.99M |
|
$2.58M |
|
$2.58M |
|
$2.58M |
|
23.23M |
|
| Cash Flow Statement Financials | |
$-10.13M |
|
$0.00M |
|
$10.91M |
|
$2.64M |
|
$3.38M |
|
$0.74M |
|
$0.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-395.28% |
|
-395.28% |
|
-223.17% |
|
-395.28% |
|
$0.11 |
|
$-0.55 |
|
$-0.54 |
|